Mylan personnel appointments
Executive Summary
VP-Generic Business Development John Deiriggi is appointed to the new position of chief operating officer of Mylan's generic subsidiary, Mylan Pharmaceuticals, the company announces. Deiriggi is a 19-year veteran of Mylan. In connection with the promotion, Exec Director of Corporate Administration Daniel Caron will take over as VP of generic business development. Additional moves include Gary Sphar to the post of exec VP and CFO of Mylan Pharmaceuticals and Brian Roman to the post of VP and general counsel of the generic subsidiary...
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.